Welcome to CDC stacks | SUPPLEMENTARY TABLE 2. Prespecified outcomes*,† for recombinant zoster vaccine (RZV) in reports submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018 - 61561 | Morbidity and Mortality Weekly Report (MMWR)
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
SUPPLEMENTARY TABLE 2. Prespecified outcomes*,† for recombinant zoster vaccine (RZV) in reports submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018
  • Published Date:
    February 28, 2019
  • Source:
    MMWR. Morbidity and mortality weekly report ; v. 68, no. 4
  • Language:
    English
Filetype[PDF-349.78 KB]


Details:
  • Supporting Files:
    No Additional Files
You May Also Like:
  1. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
    Personal Author:
    Hesse, Elisabeth M.; Shimabukuro, Tom T.; Su, John R.; Hibbs, Beth F.; Dooling, Kathleen L.; Goud, Ravi; Lewis, Paige; Ng, Carmen S.; Cano, Maria V.;
    Published:
    February 01 2019
    Source:
    MMWR Morb Mortal Wkly Rep. 68(4):91-94
    Description:
    Recombinant zoster vaccine (RZV; Shingrix), an adjuvanted glycoprotein vaccine, was licensed by the Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices for adults aged ≥50 years in October 2017 (1)...
    File Type:
    Filetype[PDF - 180.36 KB]
  2. SUPPLEMENTARY TABLE 2. Prespecified outcomes*,† for recombinant zoster vaccine (RZV) in reports submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018
    Published:
    February 1, 2019
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 68, no. 4, p.
    Description:
    Supplementary table for: Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018.
    File Type:
    Filetype[PDF - 68.84 KB]
  3. MMWR. Morbidity and Mortality Weekly Report, Vol. 68, no. 4, February 1, 2019
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    February 1, 2019
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 68, no. 4
    Description:
    National Black HIV/AIDS Awareness Day — February 7, 2019 — HIV Partner Service Delivery Among Blacks or African Americans — United States, 2016 / Shubha Rao, MPH; Wei Song, PhD; Mesfin S. Mulatu, PhD; et al. — Use of Toothpaste and Toothbrush...
    File Type:
    Filetype[PDF - 680.46 KB]
  4. SUPPLEMENTARY TABLE 1. Search strategy to identify recombinant zoster vaccine (RZV) reports of selected pre-specified outcomes in the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018
    Published:
    February 28, 2019
    Source:
    MMWR. Morbidity and mortality weekly report ; v. 68, no. 4
    Description:
    Supplements: Post-licensure safety surveillance of recombinant zoster vaccine (Shingrix) —Vaccine Adverse Event Reporting System (VAERS), United States, October 2017–June 2018
    File Type:
    Filetype[PDF - 265.31 KB]
  5. SUPPLEMENTARY TABLE 1. Search strategy to identify recombinant zoster vaccine (RZV) reports of selected pre-specified outcomes in the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018
    Published:
    February 1, 2019
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 68, no. 4, p.
    Description:
    Supplementary table for: Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018.
    File Type:
    Filetype[PDF - 32.33 KB]